BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/23/2022 1:56:15 PM | Browse: 337 | Download: 774
 |
Received |
|
2022-03-27 12:03 |
 |
Peer-Review Started |
|
2022-03-27 12:04 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2022-05-31 17:32 |
 |
Revised |
|
2022-06-30 11:39 |
 |
Second Decision |
|
2022-09-26 03:46 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2022-10-04 22:47 |
 |
Articles in Press |
|
2022-10-04 22:47 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2022-08-31 21:08 |
 |
Typeset the Manuscript |
|
2022-11-11 15:55 |
 |
Publish the Manuscript Online |
|
2022-11-23 13:56 |
ISSN |
2220-3249 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Endocrinology & Metabolism |
Manuscript Type |
Minireviews |
Article Title |
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
|
Manuscript Source |
Invited Manuscript |
All Author List |
Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo and Sadishkumar Kamalanathan |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Dukhabandhu Naik, MD, Additional Professor, Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, 4th floor, Super-speciality block, JIPMER campus, Dhanvantri nagar, Puducherry, India -605006
, Puducherry 605006, Puducherry, India. drnaik2000@gmail.com |
Key Words |
Dipeptidyl -peptidase 4; Diabetes mellitus; COVID-19; Mortality |
Core Tip |
Patients with pre-existing comorbidities, particularly diabetes mellitus (DM), are at increased risk of complications from coronavirus disease 2019 (COVID-19). Beyond their glycemic effects, Dipeptidyl-peptidase 4 inhibitors (DPP-4i) have proven effective in COVID-19 individuals with DM. Available observational studies and trials have shown a significant mortality reduction in COVID-19 patients with DM when DPP-4i were continued during the course of illness. As a result, COVID-19 individuals with DM may choose DPP-4i as the preferred anti-diabetic medication if it is not contraindicated. |
Publish Date |
2022-11-23 13:56 |
Citation |
Narayanan N, Naik D, Sahoo J, Kamalanathan S. Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control. World J Virol 2022; 11(6): 399-410 |
URL |
https://www.wjgnet.com/2220-3249/full/v11/i6/399.htm |
DOI |
https://dx.doi.org/10.5501/wjv.v11.i6.399 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345